Heather Gladue1, Virginia Steen, Yannick Allanore, Rajeev Saggar, Rajan Saggar, Paul Maranian, Veronica J Berrocal, Jerome Avouac, Christophe Meune, Mona Trivedi, Dinesh Khanna. 1. From the University of Michigan Scleroderma Program; Division of Rheumatology, Department of Medicine, Georgetown University, Washington, DC, USA; Department of Rheumatology A, Paris Descartes University, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris, France; St. Joseph's Hospital and Medical Center, Division of Pulmonary, Department of Medicine, Phoenix, AZ; David Geffen School of Medicine at UCLA, Division of Pulmonary, Department of Medicine, Los Angeles, CA; Arizona State University, Biodesign Institute, Tempe, AZ; Department of Biostatistics, University of Michigan, School of Public Health, Ann Arbor, MI, USA; and Paris XIII University, Cardiology Department, Avicenne Hospital, Bobigny, France.
Abstract
OBJECTIVE: To evaluate routinely collected non-invasive tests from 2 systemic sclerosis (SSc) cohorts to determine their predictive value alone and in combination versus right heart catheterization (RHC)-confirmed pulmonary arterial hypertension (PAH). METHODS: We evaluated 2 cohorts of patients who were at risk or with incident PAH: (1) The Pulmonary Hypertension Assessment and Recognition Outcomes in Scleroderma (PHAROS) cohort and (2) an inception SSc cohort at Cochin Hospital, Paris, France. Estimated right ventricular systolic pressure (eRVSP) as determined by transthoracic echocardiogram (TTE) and pulmonary function test (PFT) measures was evaluated, and the predictive values determined. We then evaluated patients with PAH missed on TTE cutoffs that were subsequently identified by a PFT measure. RESULTS: In the PHAROS cohort (n = 206), 59 (29%) had RHC-defined PAH. An eRVSP threshold of 35-50 mm Hg failed to diagnose PAH in 7% to 31% of patients, 50% to 70% of which (n = 2-13) were captured by PFT measures. In the Cochin cohort (n = 141), 10 (7%) patients had RHC confirmed PAH. An eRVSP threshold of 35-50 mm Hg missed 0% to 70% (n = 0-7) of patients, of which 0% to 68% (n = 0-6) were met by PFT measures. The combination of TTE and PFT improved the negative predictive value for diagnosing PAH. CONCLUSION: In 2 large SSc cohorts, screening with TTE and PFT captured a majority of patients with PAH. TTE and PFT complement each other for the diagnosis of PAH.
OBJECTIVE: To evaluate routinely collected non-invasive tests from 2 systemic sclerosis (SSc) cohorts to determine their predictive value alone and in combination versus right heart catheterization (RHC)-confirmed pulmonary arterial hypertension (PAH). METHODS: We evaluated 2 cohorts of patients who were at risk or with incident PAH: (1) The Pulmonary Hypertension Assessment and Recognition Outcomes in Scleroderma (PHAROS) cohort and (2) an inception SSc cohort at Cochin Hospital, Paris, France. Estimated right ventricular systolic pressure (eRVSP) as determined by transthoracic echocardiogram (TTE) and pulmonary function test (PFT) measures was evaluated, and the predictive values determined. We then evaluated patients with PAH missed on TTE cutoffs that were subsequently identified by a PFT measure. RESULTS: In the PHAROS cohort (n = 206), 59 (29%) had RHC-defined PAH. An eRVSP threshold of 35-50 mm Hg failed to diagnose PAH in 7% to 31% of patients, 50% to 70% of which (n = 2-13) were captured by PFT measures. In the Cochin cohort (n = 141), 10 (7%) patients had RHC confirmed PAH. An eRVSP threshold of 35-50 mm Hg missed 0% to 70% (n = 0-7) of patients, of which 0% to 68% (n = 0-6) were met by PFT measures. The combination of TTE and PFT improved the negative predictive value for diagnosing PAH. CONCLUSION: In 2 large SSc cohorts, screening with TTE and PFT captured a majority of patients with PAH. TTE and PFT complement each other for the diagnosis of PAH.
Authors: Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza Journal: J Am Coll Cardiol Date: 2009-06-30 Impact factor: 24.094
Authors: N Galiè; M M Hoeper; M Humbert; A Torbicki; J-L Vachiery; J A Barbera; M Beghetti; P Corris; S Gaine; J S Gibbs; M A Gomez-Sanchez; G Jondeau; W Klepetko; C Opitz; A Peacock; L Rubin; M Zellweger; G Simonneau Journal: Eur Respir J Date: 2009-09-12 Impact factor: 16.671
Authors: S Phung; G Strange; L P Chung; J Leong; B Dalton; J Roddy; J Deague; D Playford; M Musk; E Gabbay Journal: Intern Med J Date: 2008-11-03 Impact factor: 2.048
Authors: Eric Hachulla; Pascal de Groote; Virginie Gressin; Jean Sibilia; Elisabeth Diot; Patrick Carpentier; Luc Mouthon; Pierre-Yves Hatron; Patrick Jego; Yannick Allanore; Kiet Phong Tiev; Christian Agard; Anne Cosnes; Daniela Cirstea; Joël Constans; Dominique Farge; Jean-François Viallard; Jean-Robert Harle; Frédéric Patat; Bernard Imbert; André Kahan; Jean Cabane; Pierre Clerson; Loïc Guillevin; Marc Humbert Journal: Arthritis Rheum Date: 2009-06
Authors: Dinesh Khanna; Heather Gladue; Richard Channick; Lorinda Chung; Oliver Distler; Daniel E Furst; Eric Hachulla; Marc Humbert; David Langleben; Stephen C Mathai; Rajeev Saggar; Scott Visovatti; Nezam Altorok; Whitney Townsend; John FitzGerald; Vallerie V McLaughlin Journal: Arthritis Rheum Date: 2013-12
Authors: Scott H Visovatti; Oliver Distler; J Gerry Coghlan; Christopher P Denton; Ekkehard Grünig; Diana Bonderman; Ulf Müller-Ladner; Janet E Pope; Madelon C Vonk; James R Seibold; Juan-Vicente Torres-Martin; Martin Doelberg; Harbajan Chadha-Boreham; Daniel M Rosenberg; Vallerie V McLaughlin; Dinesh Khanna Journal: Arthritis Res Ther Date: 2014-12-10 Impact factor: 5.156